Once-a-day pill for stubborn cancer delivers a 62.5% positive response
newatlas.com
In what has already been tagged as a “game-changer” for cancer treatment, the potent once-a-day tablet known as divarasib has continued to impress at Phase 1b trial stage, outperforming not just current therapies but its previous trial results.
This is an automated archive made by the Lemmit Bot.

The original was posted on /r/science by /u/chrisdh79 on 2023-12-06 12:52:47.

Original Title: Once-a-day pill for stubborn cancer delivers a 62.5% positive response | Been tagged as a “game-changer” for cancer treatment, the potent once-a-day tablet known as Divarasib has continued to impress at Phase 1b trial stage, outperforming not just current therapies but its previous trial results.